Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma

Annals of Oncology

Volumn 13, Issue 12, 2002, Pages 1908-1914

  Zanotti, R ^a   Trolese, A ^a   Ambrosetti, A ^a   Nadali, G ^a   Visco, C ^a   Ricetti, M M ^a   Benedetti, F ^a   Pizzolo, G ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Hodgkin's lymphoma; International Prognostic Score; Prognosis; sCD30

Indexed keywords

BLEOMYCIN; CD30 ANTIGEN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0036920018     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf333     Document Type: Article

References (16)

1. Tubiana M. Hodgkin's disease: historical perspective and clinical presentation. Baillieres Clin Haematol 1996; 9: 503-530.
2. Specht L. Prognostic factors in Hodgkin's disease. Semin Radiat Oncol 1996; 6: 146-161.
3. Straus DJ, Gaynor JJ, Myers J et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173-1186.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
5. Gobbi PG, Zinzani PL, Broglia. C et al. Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer 2001; 91: 1467-1478.
6. Nadali G, Vinante F, Ambrosetti A et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12: 793-797.
7. Gause A, Pohl C, Tschiersch A et al. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 1991; 77: 1983-1988.
8. Viviani S, Notti P, Bonfante V et al. Elevated pretreatment serum levels of I1-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience. Med Oncol 2000; 17: 59-63.
9. Sarris AH, Kliche K-O, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433-440.
10. Nadali G, Tavecchia L, Zanolin E et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998; 91: 3011-3016.
11. Axdorph U, Sjoberg J, Grimfors G et al. Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease. Ann Oncol 2000; 11: 1405-1411.
12. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol 1989; 7: 1630-1636.
13. Pizzolo G, Vinante F, Morosato L et al. High serum level of CD30 molecule in the early phase of HIV-1 infection as independent predictor of progression to AIDS. AIDS 1994; 8: 741-745.
14. Federico M, Clò V, Carella AM. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy. Analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial. Leukemia 1996; 10 (Suppl 2): S69-S71.
15. Diehl V, Franklin J, Engert A et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized Trial. Blood 2001; 98: (Abstr 3202).
16. Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1161-1165.